Clinical observations, as well as data obtained from the analysis of genetically engineered mouse models, firmly established the gain-of-function (GOF) properties of certain p53 mutations. However, little is known about the underlying mechanisms. We have used two independent microarray platforms to perform a comprehensive and global analysis of tumors arising in a model of metastatic skin cancer progression, which compares the consequences of a GOF p53 R172H mutant vs p53 deficiency. DNA profiling revealed a higher level of genomic instability in GOF vs loss-of-function (LOF) p53 squamous cell carcinomas (SCCs). Moreover, GOF p53 SCCs showed preferential amplification of Myc with a corresponding increase in its expression and deregulation of Aurora Kinase A. Fluorescent in situ hybridization confirmed amplification of Myc in primary GOF p53 SCCs and its retention in metastatic tumors. We also identified by RNA profiling distinct gene expression profiles in GOF p53 tumors, which included enriched integrin and Rho signaling, independent of tumor stage. Thus, the progression of GOF p53 papillomas to carcinoma was marked by the acquisition of epithelialto-mesenchymal transition and metastatic signatures. In contrast, LOF p53 tumors showed enrichment of genes associated with cancer proliferation and chromosomal instability. Collectively, these observations suggest that genomic instability has a prominent role in the early stages of GOF p53 tumor progression (that is, papillomas), whereas it is implicated at a later stage in LOF p53 tumors (that is, SCCs). This model will allow us to identify specific targets in mutant p53 SCCs, which may lead to the development of new therapeutic agents for the treatment of metastatic SCCs.
Introduction
Non-melanoma skin cancer is the most common neoplasm in the United States with a lifetime risk nearly equal to that of all other cancers combined (Jemal et al., 2009) and has been estimated to cost the healthcare systems over 1.4 billion dollars annually (Bickers et al., 2006) . Squamous cell carcinoma (SCC) is the second most common skin cancer accounting for almost 200 000-300 000 new cases annually and the majority of deaths associated with non-melanoma skin cancers. Similar to other epithelial cancers, skin SCCs develop in a step-wise manner from pre-cursor lesions, to benign tumors (SCC in situ), to well-differentiated SCCs and, finally to poorly differentiated spindle cell carcinomas that possess increased metastatic potential.
Activating RAS mutations occur in 5-40% of sporadic skin SCCs (Pierceall et al., 1991; Spencer et al., 1995) . However, RAS mutations are found in B62% of SCCs in individuals with the DNA repair deficiency syndrome, Xeroderma Pigmentosum (DayaGrosjean and Sarasin, 2005) and in 46-76% of SCCs in psoriasis patients treated with Psoralen with UVA treatment (Kreimer-Erlacher et al., 2003; Wolf et al., 2004) . In the absence of activating RAS mutations, elevated levels of active, GTP-bound RAS have been reported in a high number of SCCs (Dajee et al., 2003) , as well as the overexpression of RAS family members (Paterson et al., 1996; Lu et al., 2006) . Thus, activation of the RAS signaling pathway frequently occurs in cutaneous SCCs and contributes to malignant conversion of these tumors.
The p53 tumor suppressor gene is frequently mutated in skin cancers and over 73% of p53 mutations found in human SCCs are missense substitutions that result in the expression of mutant forms of p53, some of which abrogate the ability of p53 to turn on targets genes involved in cell cycle arrest, apoptosis and other tumor suppression functions (Harris and Levine, 2005) . Consequently, such mutations confer a loss-of-function (LOF) to p53. However, certain p53 mutants are capable of promoting tumorigenicity when introduced into p53 null cells, suggesting that they acquire gain-offunction (GOF) properties (Sun et al., 1993) . One of the best characterized GOF mutations occurs at codon 175 (a human cancer 'hot spot' in p53) and results in an arginine-to-histidine substitution (R175H or R172H in mice). Mice engineered to express the p53 R172H mutant under the control of the endogenous p53 promoter recapitulate the spectrum of tumors observed in patients with Li-Fraumeni syndrome who carry the p53 R175H mutation (Bougeard et al., 2008) . It is unclear how various GOF p53 mutations contribute to the malignancy of skin SCCs or how these mutations co-operate with other oncogenic events such as the activation of RAS signaling during cancer progression.
We have recently generated an inducible mouse model that provides the strongest genetic evidence to date supporting GOF properties of mutant p53 in cutaneous SCCs (Caulin et al., 2007) . The advantage of this system is that tumors are initiated by a common event, the deregulation of Ras signaling by the activation of an endogenously expressed Kras G12D allele in the skin, and allows a comparison of tumor-promoting events such as the activation of the p53 R172H mutant allele or deletion of p53. The activation of the p53 R172H mutant allele resulted in the increased frequency and earlier onset of tumor formation, accelerated cancer progression and metastases relative to tumors lacking p53 (Caulin et al., 2007) . SCCs from GOF p53 mice also showed hallmark features of genomic instability (Caulin et al., 2007) and are reminiscent of SCCs that develop in mice that overexpress the mitotic kinase, Aurora Kinase A (Aurora-A) (Torchia et al., 2009) .
In this study, we analyzed GOF p53 tumors using whole genome approaches to understand how this p53 mutant promotes metastasis. We show that GOF p53 SCCs have distinct expression signatures and molecular alterations, including the gene amplification of Myc, deregulation of Aurora-A expression and the upregulation of integrin and Rho gene signaling networks compared with LOF p53 SCCs.
Results

Expression profiling of papillomas and SCCs from GOF p53 mice
In the GOF p53 SCC model, activation of mutant p53 as compared with the loss of p53 resulted in the earlier emergence and greater numbers of precursor tumors (that is, papillomas), and accelerated the malignant conversion of papillomas to SCCs with the induction of metastases (Caulin et al., 2007) . This system allows the comparison of the GOF properties of mutant p53 in absence of wild-type (wt) p53 and thus eliminates the possibility that p53 R172H mutant can act in a dominantnegative fashion.
We analyzed all tumor groups by principal component analysis as shown in Figure 1a using the most differentially regulated probe sets identified by ANOVA (Po0.001). This experiment revealed that tumors expressing mutant p53 were distinct from p53-deficient tumors, regardless of tumor stage ( Figure 1a) . Next, seven genes were selected at random for qPCR validation. As shown in Supplementary Figure 1 , there were concordant fold changes in gene expression by qPCR as observed by microarray analysis. We then performed hierarchical clustering analysis using the probe sets that were differentially regulated in papillomas (GOF vs LOF p53 genotypes, Supplementary Dataset 1) and observed that GOF p53 papillomas clustered with both LOF and GOF p53 SCCs, indicating that GOF papillomas, the precursors to SCCs, had expression profiles more similar to advanced stages of tumor progression compared with the corresponding LOF p53 papillomas (Figure 1b) . Clustering experiments using the probe sets that were differentially regulated in SCCs (GOF vs LOF p53 genotypes, Supplementary Dataset 2) showed that LOF p53 SCCs clustered together with all papillomas, whereas GOF p53 SCCs clustered in a separate branch (Figure 1c) , suggesting that LOF p53 SCCs are at a less malignant stage of tumor progression compared with GOF p53 SCCs. Overall, these profiling and clustering analyses revealed four different stages of tumor progression as determined by the type of p53 mutation (Figure 1d ) that correlate well with the kinetics of tumor development in p53 R172H/À and p53 À/À mice (Caulin et al., 2007) .
Effectors of mutant p53 in SCCs
To identify potential targets of mutant p53 in SCCs, we determined the level of overlap between papillomas and SCCs, comparing GOF vs LOF p53 tumors. We reasoned that any target genes of mutant p53 would most likely show concordant regulation in both precursor and advance tumors. First, we analyzed genes found altered in papillomas (GOF vs LOF p53 genotypes, Supplementary Dataset 1) by gene ontology (GO) terms using the web-based functional and gene annotations tools, DAVID (Huang da et al., 2009) and GOTM (Dennis et al., 2003; Zhang et al., 2004) . GO terms associated with extracellular matrix (ECM), cell adhesion and cytoskeleton were enriched in upregulated genes of GOF p53 papillomas (qo0.05) (Supplementary Dataset 3). These categories included several matrix metalloproteinases, integrins, cytokines and ECM genes, which have been collectively implicated in ECM remodeling and cancer invasion. Moreover, no significant enrichment of GO terms was observed in downregulated genes. Analysis of SCCs (GOF vs LOF p53 genotypes, Supplementary Dataset 4) did show the presence of blood vessel development, angiogenesis, cell adhesion and ECM processes (qo0.05). GO terms associated with downregulated genes included desmosomes, cell-to-cell junctions and cellular anchoring processes (qo0.05) (Supplementary Dataset 4) . Thus, both GOF p53 papillomas and SCCs showed enhanced ECM interactions. We therefore explored these interactions using gene set enrichment analysis (GSEA) with gene sets available from the Broad Institute (Mootha et al., 2003; Subramanian et al., 2005) . GSEA revealed enrichment of gene sets associated with integrin signaling and downstream Ras homolog gene family (Rho) GTPases (Figure 2a ) in GOF vs LOF p53 SCCs. Rho GTPases have a fundamental role in the regulation of cytoskeleton dynamics and other cellular function including cell cycle and cellular migration in normal and tumor cells (Karlsson et al., 2009 ). Enrichment of integrin complex genes was evident by clustering experiments showing the upregulation of these genes in both GOF p53 papillomas and SCCs (Figure 2b) . The overlap between genes differentially regulated in GOF p53 papillomas and SCCs, relative to the respective LOF p53 tumors, revealed 69 genes, which showed concordant up or downregulation (53 upregulated and 16 downregulated) (Supplementary Dataset 5) . In this list, we observed the previously identified targets of mutant p53, Rho/Rac guanine nucleotide exchange factor (GEF) 2 (Arghef2) and matrix metallopeptidase 3 (Mizuarai et al., 2006; Brosh and Rotter, 2009) . To further investigate the interconnection of these potential GOF p53 targets, we performed network analysis using the Ingenuity web-software. One such top-rated network represented the potential microenvironment and intracellular interactions, specifically those involving ECM components such as laminin, integrins, Rho GTPases and GEFs signaling pathways, which help to regulate Rho signaling ( Figure 2c ) (van der Meel et al., 2011) . Lastly, these genes may also account for more advanced stage of tumor progression observed in the gene expression profiles of GOF p53 papillomas relative to LOF p53 papillomas (Figure 1 ).
Analysis of the molecular events associated with progression in GOF and LOF p53 tumors
We compared the transition between papillomas to SCCs in both GOF (SCCs vs papillomas, Supplementary Dataset 6) and LOF p53 tumors (SCCs vs papillomas, Supplementary Dataset 7) and analyzed the genes found regulated in a similar manner between GOF and LOF p53 tumors. The overlap between Supplementary Data sets 7 and 8 represents the molecular events previously described in cancers (for example, loss-of-differentiation), as they evolve from pre-cancerous lesions (Hanahan and Weinberg, 2000) (See Supplementary Dataset 8 and Supplementary Text for further discussion on commonly regulated genes and processes).
To understand the molecular events involved in the accelerated progression of GOF p53 skin cancers, we focused on non-overlapping genes, which were deregulated in either LOF or GOF p53 tumors (SCCs vs papillomas). Analysis of downregulated genes in LOF p53 tumors primarily revealed the enrichment of ubiquitin-protein ligase activity (Supplementary Figure 2 and Supplementary Dataset 9), whereas the upregulated genes in these tumors were enriched in processes associate with mitosis, including centrosome, spindle and cell cycle checkpoint regulation events ( Figure 3a and Supplementary Dataset 9). Thus, centrosomeregulating genes such as NeK2, Aurora-A, Aurora-B and Plk-1, and spindle and mitotic checkpoint genes such as Bub1, CenpE, Cdc6 and Cdc25C were present in these categories. Consistently, Ingenuity pathway analysis showed a significant overlap of canonical pathways involving the regulation of mitosis by Plk1 and G2/M checkpoints (Supplementary Table 1 ). In summary, these results indicate that deregulation of cell cycle checkpoints may be an important event in p53-deficient SCCs as they progress from papillomas. In GOF p53 tumors (SCCs vs papillomas), GO terms associated with apoptosis, signal transduction and lipid metabolism were found in the downregulated genes ( Supplementary  Figure 2 and Supplementary Dataset 10). In contrast, terms associated with cellular movement, gene expression and post-translational protein modification were enriched in the upregulated genes ( Figure 3a and Supplementary Dataset 10). These categories included genes implicated in cancer invasion and a small number of genes associated with centrosome function. However, there was a larger set of genes related to the modification of gene expression, including regulators of chromatin modification and numerous transcription factors, and genes that regulate protein turnover, signal transduction or cellular growth and survival. Collectively, these genes were part of intracellular signaling cascades associated with cellular migration and survival present in GOF p53 SCCs as revealed by Ingenuity pathway analysis (Supplementary Table 1) .
To further characterize the dominant pathways driving cancer progression, we determined if previously identified cancer gene expression signatures were overrepresented in either GOF or LOF p53 tumors (SCCs vs papilloma). Specifically, we analyzed genes negatively regulated by wt p53 and whose expression is elevated in p53-null cells (Sur et al., 2009) . Indeed, this gene signature was enriched in LOF p53 SCCs (Figure 3b ).
Furthermore, chromosomal instability and proliferation signatures identified in numerous cancers (Carter et al., 2006; Salvatore et al., 2007) were preferentially overrepresented in LOF p53 SCCs. However, these signatures were not found in either upregulated (Figure 3b ) or downregulated genes of GOF p53 SCCs (not shown). Significant overlap was evident between upregulated genes in GOF p53 SCCs and genes associated with melanoma metastasis (Xu et al., 2008) and epithelial-tomesenchymal transition (EMT) (Jechlinger et al., 2003) ( Figure 3b ) and between downregulated EMT genes and downregulated genes in GOF p53 SCCs (16% overlap; q ¼ 0.01). In summary, the transition from precursorsto-carcinomas in GOF p53 tumors is marked by the acquisition of cellular pathways favoring EMT and metastasis, whereas the transition in LOF p53 tumors is marked by the deregulation of cell cycle control leading to genomic instability at late stages of tumor evolution. Genes observed to be deregulated in both GOF p53 papillomas and SCCs (Supplementary Dataset 10) (n ¼ 10) were analyzed using the Ingenuity web-sotware gene network algorithm. One top rated network is shown for genes that interact (compiled from published literature). Green and red symbols represent downregulated and upregulated genes, respectively. Empty nodes depict genes that are not present in the data set, but implied from literature. Solid and hatched lines correspond to direct and indirect interactions, respectively. Figure 3 EMT and metastastic signatures are preferentially enriched in GOF p53 SCCs. (a) Graphic summary of GO term analysis using GOTM and adapted from GOTM output acyclic graphs. Genelists in Supplementary Dataset 3 and 4 were compared and nonoverlapping lists generated for LOF p53 SCCs vs papillomas (1279 genes) (n ¼ 7) and GOF p53 SCCs vs papillomas (2143 genes) (n ¼ 10). Panels show analysis of GO terms from non-overlapping upregulated genes in LOF and GOF p53 SCCs. 'q' denotes adjusted P-values. Red boxes show significantly enriched GO categories and black boxes highlight non-enriched parent categories. Intermediate categories (broken lines) are omitted to simplify the presentation. (b) Lists of published cancer gene signatures were imported to Ingenuity web-software and used to determine the level of overlap with genes preferentially deregulated in LOF p53 and GOF p53 SCCs. Graphs represent the output from the ingenuity software. Blue bars denote' the q-value for each analysis. The orange dots represent the ratio of overlap with each cancer signature gene set. The threshold line denotes qo0.05 significance.
Analysis of genomic changes in GOF p53 SCCs
The induction of genomic instability is a common characteristic of the GOF properties of mutant p53 regardless of tumor type (Lang et al., 2004; Olive et al., 2004; Caulin et al., 2007) . Furthermore, acquisition of key genomic alterations may further contribute to malignancy of GOF p53 tumors. To understand how expression of GOF p53 mutants can affect the genomic integrity of tumors and to identify genes that can cooperate with mutant p53 during carcinogenesis, we performed array comparative genome hybridization (CGH) on SCCs that developed in p53
) showed the highest copy number changes per tumor compared with (Table 1) . To determine common regions of alterations, probe signals were averaged based on tumor genotype and alterations ascertained. Analyzed in this manner, SCCs-expressing mutant p53 had more gains and deletions compared with tumors with deletion of one or two p53 wt alleles (Table 1) . Thus, GOF p53 SCCs genomes appeared to be more unstable compared with tumors lacking p53, which is consistent with the aneuploidy of GOF p53 SCCs (Caulin et al., 2007) .
The majority of probes that showed alterations (Table 1) in LOF or GOF p53 SCCs were localized to chromosomes (Chrs) 3, 5, 6, 13, 15 and 18 (Figure 4) . Regardless of p53 status, copy number gains (CNGs) were observed in chr 6 in all tumors (Figure 4) . This accounted for a large proportion of probes showing amplification in p53 À/À SCCs (Table 1 ). In subsets of GOF p53 SCCs, probes corresponding to chrs 3, 5, 13, 15 and 18 showed CNGs, with the most prevalent alterations occurring on chr 3 (25%), chr 5 (25%) and chr 15 (40%) (Figure 4) . Furthermore, gains of whole regions on chrs 13 and 18 were evident in 30% of p53 R172H/À tumors. Closer examination of chr 6 alterations showed Kras CNGs in 55% of GOF p53 tumors and 53% of p53
þ /À and p53 À/À SCCs combined. Myc amplification (15qD1) was exclusively observed in 40% of both p53 R172H/ þ and p53 R172H/À SCCs (Figure 4 arrow, and Figure 5a inset). We validated Myc CNGs by qPCR on SCC DNA and observed a high level increase in gene copy number compared with non-tumor tissue or LOF p53 SCCs (Figure 5a ). Additionally, immunostaining confirmed higher levels of Myc protein in GOF p53 SCCs harboring Myc amplification (Figure 5b ). Using fluorescent in situ hybridization, we further characterized the CNGs present in the Kras and Myc loci in GOF p53 SCCs. Of the eight tumors analyzed, most tumors showed gains in both Kras (2.7-9.5 mean gene copies) and Myc (2.1-15.7 mean gene copies) (Figure 5c ). In 50% of tumors, Kras or Myc CNGs were detected as double minute or in clusters. Interestingly, one tumor showed a heterogeneous pattern of Kras and Myc amplification with regions of cells showing over 10 copies of each gene. No CNGs in the Kras and Myc loci were detected in four GOF p53 papillomas analyzed, suggesting that gene duplication of these loci occurred at a later stage of tumor development. In five different tumor biopsies from either lung or lymph nodes of GOF p53 mice, CNGs in Myc (2.7-4.5 mean gene copies) and Kras (2.8-8.5 mean gene copies) were evident (Figure 5c ). GSEA of our RNA microarray data revealed that, tumors harboring Myc CNGs showed a correlation with previously published Myc signatures (Lee et al., 2004; Kim et al., 2006) and Myc associated gene lists from the Broad Institute (Supplementary Table 2 ).
Further analysis of array CGH data revealed the presence of CNGs of the Aurora-A (AurkA) locus in 3/20 GOF p53 SCCs and the deletion of its negative Gain-of-function mechanisms of mutant p53 R172H EC Torchia et al regulator, AurkAIP1 (Lim and Gopalan, 2007) in 2/20 separate GOF p53 tumors. Moreover, CNGs in the Aurora-A activator, Nedd9 (Karthigeyan et al., 2010) , were also preferentially found in 4/20 GOF p53 SCCs. Of these, 2/20 did not overlap with tumors harboring Aurora-A or AurkAIP1 alterations. Furthermore, examination of our expression-profiling data for known Aurora-A regulators revealed downregulation of the negative regulator Chfr (Yu et al., 2005; Rao et al., 2009) in GOF vs LOF p53 SCCs (Po0.05). On the basis of these observations, we examined the expression pattern Aurora-A in GOF p53 SCCs by immunostaining. Aurora-A was readily detectable in dividing cells from p53 þ / þ tumors, localizing to spindle poles in metaphase tumor cells (Figure 6 and inset) . This pattern of expression was preserved in p53 þ /À and p53
tumors. In contrast, we observed a higher level of Aurora-A staining in p53 R172H/ þ SCC cells (See graph in Figure 6 ), but a more diffused pattern in p53 R172H/À tumor cells, reminiscent of a staining pattern observed in poorly differentiated human SCCs (Torchia et al., 2009) .
Discussion
We present in this study a comprehensive and global molecular analysis of a well-characterized progression model of metastatic skin SCCs. We used two independent microarray platforms to correlate the in vivo phenotypic presentation of GOF and LOF p53 tumors (Caulin et al., 2007) , with the molecular alterations at the RNA and DNA level that promote metastasis. This unique approach revealed the pathways involved in mutant p53-driven tumorigenesis, such as genomic stability, ECM interactions and cytoskeletal signaling. The enhanced genomic instability in GOF p53 SCCs led to the retention of specific genomic alterations targeting powerful oncogenes as Myc and Aurora-A. Furthermore, the presence of metastatic and EMT signatures coupled with the absence of chromosomal instability signatures suggests that GOF p53 SCCs acquired genomic instability at an early stage of tumor evolution, consistent with the presence of centrosome amplification, a hallmark feature of genomic instability in cancer (Fukasawa, 2005) , previously observed in papillomas that expressed the GOF p53 mutant (Wang et al., 1998; Caulin et al., 2007) . Taken together our results indicate that LOF p53 SCCs acquire genomic instability at a late stage in their tumor development, thereby delaying the emergence of metastases, which is consistent with previous reports for p53-null skin tumors (Kemp et al., 1993; Caulin et al., 2007) , whereas GOF p53 tumors acquire genomic instability at an early stage of cancer progression. It is well known that mutant p53 can induce defective cell cycle checkpoint regulation, which combined with the deregulation of Aurora-A activity or its expression may further promote genomic instability and drive the selection of other oncogenes (for example, Myc), which enhance tumor invasion and metastasis. We have shown that Aurora-A overexpression can lead to genomic instability in tumors and promote skin SCC metastasis, with the concomitant loss of p53 expression (Torchia et al., 2009) . Interestingly, amplification of Aurora-A was only observed in a small number of GOF p53 SCCs, while a much higher frequency of tumors showed altered protein expression. Thus, the regulation of Aurora-A in GOF p53 tumors may be complex and involve posttranslation mechanisms that control its overall protein level and/or activity.
The preferential amplification of Myc seen in GOF p53 primary SCCs and the presence of Myc CNGs in metastases suggest a dominant role for Myc signaling in highly malignant and metastatic SCCs. Overexpression of Myc in skin has been shown to enhance SCC formation (Rounbehler et al., 2001) and to promote genomic instability in tumor cells (Prochownik and Li, 2007) . Alone, overexpression of Myc can enhance invasiveness of breast carcinoma cells (Cho et al., 2010) and the amplification of Myc has been associated with poor patient prognosis and more aggressive tumors (Haughey et al., 1992; Kozma et al., 1994; Yakut et al., 2003; Ozakyol et al., 2006; Boelens et al., 2009) . Moreover, MYC amplification was reported in over 50% of SCCs found in organ transplant recipients, which are 65-250 times more likely to develop highly malignant and metastatic SCCs (Euvrard et al., 2003; Boukamp, 2005) .
To date, few universal mechanisms or effectors have been described to account for the highly metastatic tumors expressing the p53 R172H mutant in various noncutaneous tissues (Liu et al., 2000; Hingorani et al., 2005; Zheng et al., 2007; Doyle et al., 2010) . This may reflect a propensity of mutant p53 to act in a tissue or tumor-stage dependent manner. Our studies identified numerous cellular processes that were preferentially deregulated in GOF p53 SCCs and two previously identified targets of mutant p53, Arhgef2 and matrix metallopeptidase 3 (Mizuarai et al., 2006; Brosh and Rotter, 2009 ), both of which have been implicated in promoting invasive cancer phenotypes (Ramos et al., 2002; Birkenfeld et al., 2008) . Further, it has been established that remodeling of the extracellular environment is crucial for the development of metastatic tumors (Denys et al., 2009) . Hence, any alterations in the ECM coupled with specific intracellular signaling events will have a critical role in increasing the invasive potential of mutant p53 tumor cells. On the basis of our microarray analyses, both integrin signaling and its downstream mediators (for example, Rho GTPase and GEFs) may contribute to the invasive phenotype of GOF p53 SCCs, which is consistent with previous studies (Muller et al., 2009; Sauer et al., 2010) .
Currently, histopathological evaluation may be insufficient to determine if highly malignant skin tumors will recur or undergo metastasis. Our study shows that the mutational status of p53 in tumor cells dictates which molecular pathways or genetic alterations can predominate in highly malignant and metastasis prone skin tumors. Moreover, our data suggest that crosstalk between Aurora-A, Myc and effectors of mutant p53 occur in GOF p53 SCCs. Thus, Aurora-A can upregulate Myc , which can upregulate Aurora-A protein levels (den Hollander et al., 2010) . Myc also regulates RhoA expression (Chan et al., 2010) and Aurora-A can regulate Arhgef2 activity (Birkenfeld et al., 2007) , thereby affecting tumor cell invasiveness. This potential oncogene crosstalk offers an opportunity for therapeutic intervention depending on the p53 mutational status of the patient's tumor. For example, defective checkpoint regulation in cancer cells may be exploited to selectively kill tumor cells with wt or LOFmutant p53 (Cheok et al., 2011) . However, unlike wt or LOF p53 tumors, the treatment GOF p53 tumors with p53 pathway activators such as nutlin-3 (Shen and Figure 6 Aurora-A is aberrantly expressed in GOF p53 SCCs. Representative detection of Aurora-A by immunohistochemistry (IHC) in tumor sections of p53 Maki, 2011) may have devastating effects, as previous studies have shown that GOF-mutant forms of p53 are also stabilized by nutlin-3 (Terzian et al., 2008) . However, nutlin-3 in combination with an Aurora Kinase inhibitor such as VX680 may be very effective in selectively killing GOF p53 tumors (Cheok et al., 2010) . Alternatively, drugs such as Prima-1, which restores wt activity to mutant p53 (Saha et al., 2010) in combination with small molecule inhibitors targeting Myc interactions with its binding partner Max (Shi et al., 2009) , may be useful in treating SCC metastases with mutant p53 and MYC amplification.
In summary, we have compared skin SCCs by the type of p53 mutation (either LOF or GOF) present in these tumors and revealed the genetic and molecular alterations that are specific for GOF p53 tumors. This analysis further suggests that the pathways governed by Aurora-A, Myc and integrin/Rho signaling have an important role in mediating the oncogenic properties of GOF p53 in skin tumors and offer potential strategies for therapeutic intervention in aggressive and metastatic SCCs. Our GOF p53 model offers a unique tool to test p53-based therapeutic strategies in vivo and future studies will determine if skin SCCs harboring GOF p53 mutations can be selectively targeted by therapies against Aurora Kinase or Myc signaling pathways.
Materials and methods
RNA and DNA microarray profiling and qPCR analysis RNA and DNA microarray profiling was performed at the Baylor College of Medicine Microarray Core Facility. Tumor RNA was isolated, processed for hybridization to Affymetrix Mouse 430 2.0 genechips. Expression microarray data were processed using dchip, Genespring GX v11 and Ingenuity (www.ingenuity.com) software. GO terms were analyzed using DAVID (http://david.abcc.ncifcrf.gov) and GOTM (http:// bioinfo.vanderbilt.edu/gotm) web-based software. Published gene lists were imported into Ingenuity software to determine the level overlap with gene lists generated from the analysis of expression microarray data. GSEA was performed in Genespring GX v11 software using imported gene sets from the Broad Institute (www.broadinstitute.org). Array CGH analysis was performed as previously described using the Agilent CGH Analytics V3.4 software (Agilent Technologies, Santa Clara, CA, USA) (Torchia et al., 2009) . The ADM-2 aberration algorithm was applied with the threshold set to six in order to determine regions of amplification or deletion in tumors (Torchia et al., 2009) . Tumor DNA or cDNA was used for qPCR analysis using a Roche Lighcycler 2.0 system (Roche Diagnostics Corporation, Indianapolis, IN, USA). Myc gene copy number was normalized by detection of Pgam1. See Supplementary Text for probe sequence and additional details on microarray experiments.
Immunohistochemical analysis
Immunostaining was performed as previously described (Torchia et al., 2009) . The antibodies used were against Myc (Sc-764, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and Aurora-A (610938, BD Bioscience, San Jose, CA, USA). Quantification of Aurora-positive cells was performed using a three-point scale (1 ¼ low, 2 ¼ medium and 3 ¼ high) for staining intensity multiplied by number of positive cells. In all three separate fields were evaluated for each sample and final score averaged. See Supplementary Text for additional details.
Fluorescent in situ hybridization analyses Detection of Kras and Myc copy number changes was conducted at the University of Colorado Cancer Center Cytogenetic Core using BACS encoding the murine Kras and Myc loci. Stained slides were analyzed by fluorescence microscopy. Mean copy numbers per cell were determined using at least 50 nuclei per specimen. See Supplementary Text for additional details.
Statistical analyses
Statistical tests were performed using dChip, Genespring, DAVID, GOTM, Graph Pad Prism v5.0 (GraphPad Software, Inc., La Jolla, CA, USA), and Ingenuity software. A 'q-value' denotes adjusted P-values derived from multiple testing corrections (Hochberg and Benjamini, 1990) .
The tumors analyzed in this study were derived as described in (Caulin et al., 2007) ;p53 R172H/À mice (Caulin et al., 2007) will be referred by the p53 genotype (for example, p53
R172H/À
). p53 À/À tumors will also be referred as LOF p53 SCCs and p53 R172H/À tumors as GOF p53 tumors.
